ArticleJournal of pharmacy & bioallied sciences2025
An
Article in Journal of pharmacy & bioallied sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: OSCC stands as a prominent oral malignancy that develops because of lifestyle behavior and microbial activity. The pathogenesis of OSCC receives attention through modern research since Candida species reportedly contribute to the development of OSCC through inflammatory responses and nitrosamine generation and epithelial tissue malformation. Materials and Methods: Sixty subjects participated in this Results: Out of the 30 Group A samples, 80% (24/30) demonstrated candidal growth where Candida albicans constituted 70.8% of strains and Candida tropicalis made up 16.7% alongside Candida glabrata counting for 12.5%. The overall candidal growth among participants in Group B was limited to 30% (9/30) as C. albicans constituted 88.9%, whereas C. glabrata accounted for 11.1%. The incidence of candidal colonization proved markedly higher among the high-risk group compared to controls according to statistical analysis ( Conclusion: The numbers of Candida species, particularly C. albicans, rise substantially within the oral environments of patients dealing with potentially malignant disorders. The obtained data support the possibility that oral cancer development may be related to candidal colonization, thus demanding additional studies on this association.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.